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Abstract: Neuronal nitric oxide synthase (nNOS) produces the key signalling mediator nitric oxide, (NO). This gaseous, free radical molecule modulates a vast array of
biological processes, from vascular pressure to immune responses and neurological
signalling cascades. Overproduction of NO has been implicated in conditions including Alzheimer’s disease, Parkinson’s disease and schizophrenia. Inhibition of nNOS
therefore offers a potential therapeutic approach for treatment of these conditions. This endeavour is made more complex by the fact that there are two other isoforms of nitric oxide synthase (NOS), endothelial NOS (eNOS) and inducible NOS (iNOS). The selectivity of nNOS inhibitors is therefore a key concern for therapeutic development. This review explores recent advances in the field of selective nNOS inhibition. A particular focus is placed on computational
approaches towards the rational design of selective nNOS ligands with improved pharmacokinetic properties. These
ligands have been targeted at four key binding sites of the nNOS enzyme - the tetrahydrobiopterin, calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH) and arginine binding sites. The binding sites, and the compounds
used to inhibit them, will be discussed in turn, along with the computational methods which have been employed in the
field of nNOS inhibition.

Keywords: Binding pockets, in silico, neuronal nitric oxide synthase (nNOS), selective inhibition.
1. INTRODUCTION
1.1. NOS Function
Nitric oxide (NO) is a small, gaseous, free radical molecule which acts as a vital secondary messenger for a variety
of physiological functions. NO exerts its signalling effect by
stimulation of the cyclic guanosine 3’,5’-monophosphate
(cGMP) pathway, causing an increase in production of
cGMP and activation of phosphorylation events [1-3]. cGMP
signalling cascades have been directly linked to a plethora of
neuronal and cardiovascular actions, including long term
memory formation and vascular pressure regulation [4]. NO
is also directly employed as a reactive oxygen species (ROS)
to combat foreign pathogens and tumours [5].
NO is produced by a family of enzymes called the nitric
oxide synthases (NOS). These enzymes convert L-arginine
and molecular oxygen to NO and L-citrulline via a Nhydroxy-L-arginine (L-NOHA) intermediate (Fig. 1) [6].
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There are three mammalian isoforms of the enzyme. Endothelial NOS (eNOS), produces NO for use in the vascular
system where it regulates vasodilation and vascular pressure
[7]. eNOS has also been observed in the lungs and trachea
where it modulates ciliary motility and smooth muscle relaxation [7]. Neuronal NOS (nNOS) is localized primarily in
the brain and central nervous system (CNS). The NO produced by this isoform is used for neurogenesis and regulation
of the cholinergic, dopaminergic and glutaminergic signalling pathways, among others [8]. The final isoform, inducible nitric oxide synthase (iNOS), produces NO in response
to infection of host cells by bacteria or other pathogens. This
NO has been observed to have both pro and antiinflammatory effects and also some tumour suppression activity [9].
All three isoforms exist as homodimeric enzymes, with
each monomer consisting of an N-terminal oxygenase domain and a C-terminal reductase domain [10]. These domains are connected by a calmodulin binding region (CBR).
The oxygenase domain contains a non-catalytic zinc, tetrahydrobiopterin (BH4) and the catalytic active site, which
binds L-arginine and a heme moiety. The reductase domain
employs nicotinamide adenine dinucleotide phosphate
(NADPH), flavin adenine dinucleotide (FAD) and flavin
mononucleotide (FMN) to shuttle electrons from the reductase domain to the iron at the centre of the heme co-factor in
the catalytic active site [6]. In the active site, L-arginine then
© 2015 Bentham Science Publishers
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Fig. (1). Production of NO from L-arginine and molecular oxygen.

becomes oxidised to L-citrulline and NO is produced [11].
The zinc ion in the oxygenase domain, while not directly
participating in the catalytic cycle, provides a coordination
site for four symmetry related cysteine residues, two from
each monomer. This tetrahedral coordination sphere is an
integral part of the dimer interface of NOS enzymes [12-14].
Activation of eNOS and nNOS is dependent on
calmodulin (CaM) binding [15]. This binding event is controlled by calcium levels where an increase in cellular calcium concentration facilitates formation of the NOS/CaM
complex. Without CaM the enzymes are far less efficient at
electron transfer and activity notably decreases [16]. This
system offers a regulatory mechanism for the constitutively
expressed eNOS and nNOS. In contrast, CaM is bound to
iNOS, even at low calcium concentrations, and as this isoform is inducibly expressed, it is regulated at the transcriptional level [17].
The mechanism of NO production is conserved across all
three isoforms with the heme iron in the arginine binding site
playing a central role in the catalytic cycle. Although some
of the specifics of this pathway have yet to be elucidated, a
proposed cycle is provided below, adapted from the literature
[17-19]. The exact nature of the oxidative species is still unclear [18].
The proposed cycle begins with the heme iron in the resting (III) oxidation state. An electron, transferred from the
reductase domain, reduces the heme iron to the (II) oxidation
state. Molecular oxygen binds to the iron and subsequent
electron transfer from BH4 and protonation generates an iron
peroxy complex. Protonation, electron transfer (from the
porphyrin (Por) ring) and loss of water generates the iron
(IV) complex with a doubly bound oxygen atom [15, 18].
The iron (IV) complex then reacts with L -arginine to form
the intermediate L-NOHA and iron (III) is regenerated. A
similar sequence of steps is then repeated, starting with the
transfer of an electron from the reductase domain, reducing
the heme iron to the (II) oxidation state. The reaction sequence changes once the iron (III) peroxy species is generated, which reacts with L-NOHA to produce L-citrulline and
an iron (III) nitrosyl species. In the final steps, the NO radical is formed and released along with the regeneration of
iron (III) and the cycle begins again.
1.2. NOS and Disease
Uncoupling of the NOS electron transport chain, or overproduction of NO by the NOS enzymes, has been linked to a

wide variety of neurological and physiological disorders
[20,21]. In the absence of BH4 the NOS electron transport
chain becomes uncoupled, which results in the production of
ROS such as superoxide, O2-. This superoxide can further
react to generate reactive nitrogen species (RNS), such as
peroxynitrite (ONOO-) [11,19,22]. Both of these species can
inflict oxidative stress on cells, resulting in translation errors
and protein aggregation. This may occur with any of the
NOS isoforms. In situations where the NOS enzyme is
overly active, these oxidative stress events happen more rapidly resulting in accelerated cellular damage.
Oxidative damage caused by iNOS generated NO has
been linked to auto immune and inflammatory disorders including rheumatoid arthritis [23]. Excessive NO production
by iNOS is also a contributory factor in the onset of septic
shock [9]. Over active nNOS can result in hyperphosphorlyation and accumulation of tau proteins, an event which has
been implicated in Alzheimer’s disease [24,25]. In addition
oxidative damage caused by over active nNOS leads to dysregulation of the signalling pathways and has long been associated with a variety of neurological conditions including
Parkinson’s disease [26,27]. Elevated levels of NO metabolites have also been observed in the brain tissue of schizophrenic patients [28]. eNOS has not been directly identified
as a “disease gene”, however oxidative damage potentially
caused by overactive eNOS has been observed in a range of
cardiovascular diseases [29].
1.3. NOS Binding Pockets and Ligand Design
Partial inhibition of overactive NOS enzymes may slow
the production of damaging ROS and RNS and prevent the
build-up of potentially harmful levels of NO. To date several
families of small molecule inhibitors have been developed
for this purpose. These inhibitors have been targeted at four
potential therapeutic target sites of the NOS enzymes. These
are:
1. The BH4 site, located in the oxygenase domain, which
binds the co-factor BH4.
2. The CaM binding site, which sits between the oxygenase
and reductase domains.
3. The NADPH binding site, which is located in the reductase domain.
4. The catalytic active site, which is located in the oxygenase domain and binds arginine for production of NO.
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These four sites have been exploited for the design of
selective nNOS ligands using structure based drug design
(SBDD) and ligand based drug design (LBDD) approaches. SBDD encompasses the use of techniques such
as molecular docking to predict protein-ligand [30] interactions, and de novo design of novel compounds. In contrast,
LBDD focuses on available ligand based experimental information and includes techniques such as pharmacophore
design and quantitative structure activity relationship
(QSAR) approaches [31]. Both SBDD and LBDD have
resulted in some notable successes in nNOS inhibitor development with hit compounds displaying good levels of
activity and selectivity. The pharmacokinetics (PK) properties and blood brain barrier (BBB) penetration of nNOS
inhibitors is also of critical importance. The hit to lead
process often focuses on examining the PK properties of a
hit compound and employs computational and medicinal
chemistry techniques that result in compounds with lower
molecular weights, lower numbers of hydrogen bond (HB)
donors/acceptors and increased lipophilicity. Some nNOS
inhibitors which have shown promising efficacy and selectivity have undergone structural modifications in order to
improve their PK properties and make them more attractive
for clinical use.

Fig. (2). Proposed NOS catalytic cycle (where Por=porphyrin).
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Previous reviews in this area have focused on the medicinal chemistry and SAR development of inhibitors for the
three NOS isoforms [32,33]. This review will discuss the
classes of inhibitors developed for each of the four nNOS
therapeutic target sites, their potential interactions with the
target site and the role computer aided drug design has
played in the process of selective nNOS inhibition. The PK
properties of some of the most efficacious nNOS inhibitors
will also be examined.
2. NOS BINDING SITES
2.1. BH4 Binding Site
Tetrahydrobiopterin, BH4 (Fig. 3), is a pterin ring containing prosthetic group which is crucial for NOS function. It
participates in electron transfer during NO production,
(Fig. 2), and also plays a role in NOS dimer formation and
stabilisation, which is necessary for enzyme activation [34].
Owing to the importance of the BH4 binding site in NOS
enzymes, efforts have been made to target it using various
substituted pterins. Matter et al. developed a series of 65 4amino pteridine and 4-oxo pteridines, and examined their
inhibitory effects on recombinantly produced NOS protein
[35-37].
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Fig. (3). Tetrahydrobiopterin.

In the absence, at the time, of any experimentally derived
protein crystal structure for nNOS, Matter et al. made use of
homology modelling to rationally develop these 65 inhibitors. Murine iNOS and bovine eNOS [14,38] crystal structures were used as templates with a sequence homology to
human nNOS of 52.19% and 57.34% respectively. Utilising
their human nNOS homology model, Matter et al. [36] developed 3D-QSAR models, and performed comparative molecular field analysis (CoMFA) and comparative molecular
similarity index analysis (CoMSIA) to correlate molecular
property fields to biological activities. The models were developed to provide guidelines and activity predictions for
novel nNOS inhibitors. The preferred model identified one
large sterically favourable region matching with the requirement for pterin binding. A series of the predicted inhibitors
were synthesised and tested.
One of the most efficacious and selective compounds to
result from this study was compound 1 (Fig. 4) Compound 1
[36] had IC50 values of 5 µM, 214.2 µM and 31.7 µM for
porcine nNOS, bovine eNOS and human iNOS, respectively.
It was suggested that this selectivity was based on a one residue difference between the isoforms. In eNOS residue 106 is
a Val, whereas iNOS and nNOS contain Met in the equivalent position. The added steric bulk of the valine residue in
eNOS may make binding of compound 1 to eNOS less favourable than binding to either iNOS or nNOS. No explanation was provided in this initial publication regarding compound selectivity for nNOS over iNOS.
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With a clear and detailed knowledge of the key interactions within the binding site, the group refined their previous
inhibitor family and devised four key scaffolds (A1, A2, T1
and T2), which attempted to mimic the interactions of BH 4
with the nNOS binding site (Fig. 6) [37].
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Fig. (4). Selective nNOS inhibitor, compound 1 [36].

In a subsequent publication, Matter et al. [37] presented
the key interactions for BH4 in the crystallised rat nNOS BH 4
binding site (Fig. 5). The strongest interaction for BH4 was
determined to occur with a tryptophan, Trp678. A π-π interaction was observed between this residue and BH4 at a distance of 3.6 Å. An extensive network of HB interactions was
also identified. N-3 of BH4 forms a direct HB with the carboxylate of the heme moiety and a solvent mediated interaction also exists between the same propionate group and the
C-4 carbonyl. This carbonyl group directly HBs with
Arg596. The primary amine at C-2 interacts with the heme
propionate and HBs with Trp678. Matter et al. described the
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Fig. (5). Rat nNOS BH4 binding site key residues (PDB: 4D2Y)
with BH4 and heme. The structural water which mediates the dihydroxypropyl interaction with HisB692 has been included [37]. All
images generated with Pymol [39].
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Fig. (6). Refined inhibitor scaffolds based on BH4 interactions with
the rat nNOS binding site [37].

A variety of compounds were developed based on these
scaffolds which showed an array of selectivities and potencies against nNOS [37]. The assay work was conducted using the human nNOS isoform. Once again compound 1
(Fig. 4) proved to be both efficacious against, and selective
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for, human nNOS. The IC50 for this compound against human nNOS was 3.68 µM with a 58.20 and 8.62 fold, selectivity over human iNOS and human eNOS, respectively.
Compound 1 was a member of the T1 scaffold family shown
above (Fig. 6).
The binding mode of compound 1 in the rat nNOS BH4
site was predicted using docking [37]. The key predicted
interactions for compound 1 were similar to the X-ray validated interactions of BH4 with the rat nNOS binding site.
The primary amine group HBs to the heme carboxylate and
also to the Trp678 residue. The hydrogen on N-8 interacts
with Val677. The C-4 carbonyl of BH4 is replaced by a C-4
NH, which breaks the HB interaction with Arg596. The large
p-chlorophenyl group is accommodated by a pocket formed
by TrpB306, Met336 TrpB676 and Glu694 (Fig. 5). This
pocket plays a key role in the selectivity of compound 1 for
nNOS over eNOS and iNOS. Replacement of Met336 with a
valine (as in eNOS) resulted in lower binding affinity as previously suggested by Matter et al. [36].
The basis for NOS selectivity of the A1, A2, T1 and T2
scaffolds (Fig. 6) was further explored and three key substituent groups were identified as having an impact on compound selectivity [37]. These were:
1. Bulky, hydrophobic substituents at R2 or R3 increased
selectivity for nNOS over eNOS and iNOS on scaffold
T1 and T2
2. Substituted amines at R1 (scaffold A1 and T1), are preferred over oxo groups (scaffold A2 and T2)
3. Hydrophobic electron rich groups at R3 increased binding for all scaffolds
The work of Matter et al. established the BH4 binding
site as a validated target site for selective nNOS inhibition.
However, much of the subsequent literature has focused on
other NOS binding sites.
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2.2. Calmodulin Binding Site
CaM binding to NOS enzymes is an integral part of their
function. The calmodulin binding region (CBR) of the enzymes is a ~25 amino acid sequence located between the
oxygenase and reductase domain [40]. CaM binding allows a
70 Å conformational change to occur in the NOS proteins, as
determined by NMR spectroscopy and hydrogen deuterium
exchange mass spectrometry [41,42]. This conformational
change facilitates the transfer of an electron from the final
reductase partner, FMN, to the heme moiety in the oxygenase domain of another NOS monomer as illustrated in the
schematic (Fig. 7) [16].
The interaction between the NOS proteins and CaM has
been explored using crystallography and computational studies. Human eNOS binds to CaM using the classical 1-5-8-14
motif [43,44] with Phe496, Ala500, Val503 and Leu509 of
eNOS forming critical interactions with CaM [45]. The
alignment of the three NOS calmodulin binding domains is
shown below, with the 1-5-8-14 residue highlighted in each
sequence (Table 1). The 1-5-8-14 residue motif is conserved
precisely in human nNOS and eNOS, while there are two
residue changes in the iNOS motif. The iNOS sequence contains more hydrophobic residues than either of the constitutive isoforms, which may explain the higher affinity of iNOS
for CaM [45].
These CBRs of the NOS proteins have been suggested as
a possible therapeutic target site for NOS inhibition [40,4648]. The residue differences between the nNOS CBR and the
eNOS and iNOS CBR may make selective nNOS inhibition
of this site possible. There are two principle strategies focused on CaM. The first is to design molecules that bind to
CaM itself and prevent it binding to its recognition site on
the NOS proteins. Some of the compounds tested for this
purpose include the wasp venom peptide mastoparan, the bee
venom peptide melittin and monobutyltin trichloride (com-

Fig. (7). CaM mediated hinge of NOS proteins. The NOS protein is shown in its dimer form, with one monomer in grey and the other in
white.
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pound 2, Fig. 8) [40]. These compounds were observed to
decrease the levels of CaM available to nNOS in an isolated
system, with Ki values of 5 nM, 3nM and 8µM for CaM respectively. However, this method of NOS inhibition is not
selective for nNOS as the compounds bind to CaM and not
to the NOS enzymes themselves.
Table 1.

CaM binding regions of the human NOS isoforms
with the 1-5-8-14 motif highlighted in bold.

Isoform (Residues)

Alignment

Human iNOS (412-431)

REIPLKVLVKAVLFACMLMR

Human eNOS (493-512)

RKKTFKEVANAVKISASLMG

Human nNOS (732-751)

RAIGFKKLAEAVKFSAKLMG

O

N

Cl
Cl

Sn

Cl

Fig. (8). Monobutyltin trichloride, compound 2 and Tamoxifen,
compound 3.

An alternative approach is to design an inhibitor which
competitively binds to the CBR of the NOS proteins, thus
preventing CaM binding. This method may be more favourable as it offers the possibility of selective nNOS inhibition
and would also avoid interfering with other CaM signalling
pathways not related to NOS. These pathways include many
vital physiological functions such as muscle contractions,
and therefore non-specific CaM inhibition may not be clinically desirable. The breast cancer treatment Tamoxifen
(compound 3, Fig. 8) was found to bind to the nNOS CBR
with a reduction in enzyme activity in the range of 10-30%
observed [40]. No selectivity data was presented in this publication.
Some studies have also been conducted on NOS CaM inhibition using synthetic peptides which were 19-28 residues
in length. These sequences were not computationally designed but were observed to bind to the eNOS CBR and prevented CaM from interacting with the eNOS enzyme, thus
inhibiting NO production. [49] Other non-computationally
derived compounds used to inhibit NOS/CaM interaction
include compound 4 (Fig. 9) which was reported to have an
IC50 of 1.99 µM against the CaM site of recombinant rat
nNOS [50].
The CBR of nNOS has not been as extensively studied as
other pockets such as the arginine binding site for nNOS
inhibition. One of the key challenges associated with targeting the CBR region of nNOS is generating significant isoform selectivity. In addition, the design of compounds to
disrupt protein-protein interactions is also inherently difficult
no matter what the target [51].

Fig. (9). Competitive CaM inhibitor, compound 4 [50].

2.3. NADPH Binding Site
NOS catalysis is driven by the reduction of NADPH,
which binds to the reductase domain of NOS enzymes. The
NADPH binding site therefore offers a potential intervention
point at which the NOS catalytic cycle could be halted, thus
inhibiting enzyme activity. Beaumont et al. [52] developed a
nanotrigger, NT1, to monitor enzymatic activity at this site.
NT1 contains a conjugated, photoactivatable chromophore
substituted with two donor groups that replaced the
nicotinamide moiety of NADPH (Fig. 10) [52-54]. This
compound has the ability to initiate the redox reaction,
triggered by a short laser pulse, leading to enzymatic activity
with redox reaction. Subsequently, Beaumont et al. [54]
assessed the selective binding of NT1 to nNOS using
fluorescence measurements and molecular modelling.
Molecular dynamic (MD) simulations revealed that the
regulatory Phe1395 (rat nNOS) flipped away from FAD
upon NT1 binding, bringing NT1 and FAD into close
proximity. A number of HBs stabilised the NT1 interaction,
including those between the terminal phosphate group and
Arg1400, Arg1314, and Arg1284. The amide carbonyl
oxygen formed a HB with Arg1010, while the terminal
amino group interacted with Asp1393 and Ser1176. The
authors proposed the use of NT1 for time resolved X-ray and
other cellular applications including the design of specific
activators or inhibitors of enzymatic activities.

Fig. (10). Nanotrigger NT1 [52] and nanoshutter NS1 [55], compound 5 and 6. The structural motif on the right of the image binds
to the NADPH site in NOS proteins, while the left portion of the
compound acts as the chromophore.

Subsequently, Li et al. [55] examined the use of a
nanoshutter, NS1, (Fig. 10) which also targets the NADPH
site of nNOS. Here a nucleotide moiety, mimicking NADPH,
is linked to a conjugated push-pull chromophore with non-

Computational Development of Selective nNOS Inhibitors

linear absorption properties. The development of NS1 was
guided by molecular modelling studies which replaced the
1,4-diaryl-butadiene moiety of NT1 with a stilbene moiety
[55]. The authors proposed that employing a nitro group as
the terminal electron acceptor would block electron flow and
hence inhibit NOS activity. NS1 did indeed inhibit NOS activity and was shown, using molecular docking and 10 ns
MD simulations, to fit into the narrow NADPH site of
nNOS. The key interactions across the simulation again involved the conserved Arg residues (Arg1400, Arg1314,
Arg1284, Arg1010) in the NADPH binding site. NS1 represents a new class of NOS inhibitor and, as a fluorescent
compound with 2-photon excitation properties, NS1 has potential for use in NOS imaging in living tissues when bound
to constitutive eNOS or nNOS.

Current Medicinal Chemistry, 2015, Vol. 22, No. 1
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nNOS was elucidated in 2003 (PDB code 1OM4, unpublished article) along with the binding modes of arginine like
inhibitors in rat nNOS. (PDB code 1K2R, unpublished article). This represented a significant advance in the field of
NOS inhibition as, for the first time detailed information
describing the rat nNOS ligand binding pocket was available.
An image of this arginine binding site, with L-NNA bound,
is provided in Fig. (13).

2.4. Arginine Binding Site
2.4.1. Guanidinium Containing Inhibitors
A large portion of contemporary literature in the area of
nNOS inhibition has focused on arginine analogues
[32,56,57]. These compounds act as competitive inhibitors of
the NOS isoforms by mimicking the interactions of the enzyme’s natural substrate. One of the first compounds developed in this area was Nω-nitro-L-arginine (L-NNA) Fig. (11).
NH
O2N

N
H

N
H

O
OH
NH2

Fig. (11). L-NNA (Compound 7), one of the earliest arginine mimics studied for NOS inhibition [58].

L-NNA has a potent effect on eNOS resulting in severe
hypertension and hence a number of derivatives based on LNNA were developed in order to improve selectivity for
nNOS [59]. Modifications included replacing the carboxylic
acid functionality with a methyl ester and substitution of the
nitro group for a methyl group. However, these compounds
continue to suffer from poor isoform selectivity and have
pharmacokinetic properties which make them unattractive as
potential therapeutics [60].

Fig. (12). Bovine eNOS with L-NNA (compound 7) bound with
heme and the ligand. (PDB:8NSE) [61].

In an attempt to improve the potential of the L-NNA class
of NOS inhibitors, the precise binding mode of L-NNA with
bovine eNOS was deduced via crystallization in 2001 [61]. It
was observed that L-NNA retained the same HB pattern as
the natural substrate, L-arginine, with HBs forming between
the Glu363 and the guanidinium moiety and between the αamino group on the inhibitor and the heme propionate in the
binding site. Thirteen non bonded interactions were observed
between L-NNA and the binding site, all involving the nitro
group and Pro336, Phe355, Ser356 and Gly357 (Fig. 12).
The eNOS inhibition studies were the first step towards understanding the key binding elements necessary for selective
nNOS inhibition using the L-NNA family of inhibitors.
The vast majority of subsequent nNOS inhibition studies
have been conducted using the rat isoform of nNOS [62,63]
or on a homology model of the human nNOS based on the
rat nNOS structure [37,64]. The crystal structure showing the
binding mode of the natural substrate, arginine, with rat

Fig. (13). Rat nNOS arginine binding site with the L-NNA (compound 7) bound (PDB: 1K2R). Waters involved in solvent mediated
interactions between Asp597 and L-NNA have been included. BH 4
has been omitted for clarity.
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Glu592 (Glu363 in bovine eNOS) was observed to form
several HB interactions with the nitro guanidino group of the
L-NNA inhibitor. Asp597 was also involved in binding via
water mediated electrostatic interactions with the primary α
amino group of the inhibitor. The C terminal carboxyl group
of L-NNA undergoes HB with Gln478, Arg481 and Ser477
while the side chain amino group interacts via a water molecule with the heme propionate [65].
The availability of both bovine eNOS and rat nNOS crystal structures allowed for detailed selectivity studies of the LNNA based inhibitors. Flinspach et al. [65] observed Ki values of 0.13 µM, 0.12 µM and 0.07 µM for rat nNOS for
compounds 8, 9 and 10 respectively (Fig. 14). These same
compounds had Ki values of 200 µM, 300 µM and 130 µM
respectively for bovine eNOS.
In the rat nNOS binding site, the inhibitors bound in a
manner similar to that observed for L-NNA. The guanidine mimic made a bifurcated HB with Glu592. The
nitro group of the inhibitors made an additional HB with
the protein backbone, strengthening the interaction of the
inhibitors with the binding site. In bovine eNOS the in-

Curtin et al.

hibitors make the same interactions with the equivalent
glutamic acid, Glu363. In eNOS, either the guanidine to
glutamate bond, or the nitro to backbone HB is stretched
slightly (~3.2 Å) which partly explains the selectivity of
the compounds. The most important difference between
eNOS and nNOS however was thought to be the replacement of Asp597 in nNOS with Asn368 in eNOS. It was
hypothesised that the presence of the negatively charged
residue in nNOS encouraged the inhibitors to adopt a
curled configuration. This allowed the α amino group on
the inhibitors to be stabilised by both Asp597 and Glu592
in nNOS. In eNOS, this dual stabilisation was not possible
as the aspartic acid was replaced by an asparagine [65].
The extended binding conformation of compound 10 in
eNOS and its curled binding conformation in nNOS are
shown in Fig. (15).
Building on these observations Ji et al. made use of compound 10 and molecular interaction field (MIF) analysis to
examine the binding sites of rat nNOS, bovine eNOS and
human iNOS [66]. Probes covering hydrophobic, steric and
HBA/HBD interactions were used to calculate MIFs in the

Fig. (14). Compounds 8, 9 and 10 used by Flinspach et al. to examine the basis of selectivity between nNOS and eNOS [65].

Fig. (15). Bovine eNOS with compound 10 bound in extended conformation (PDB: 1P6N) vs rat nNOS with compound 10 bound in curled
conformation (PDB:1P6J). Notice the proximity of the primary amine of the inhibitor to E592 in rat nNOS (2.8 Å), while the equivalent primary amine is further removed from E363 in bovine eNOS (5 Å) [65].
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active sites of the three NOS isoforms. The most important
determinants for rat nNOS selectivity were identified as hydrophobic and charge-charge interactions [66].
Binding modes were explored by flexibly docking 25
known NOS inhibitors (including the dipeptides shown in
Fig. 14) into the binding site of the three NOS isoforms using AutoDock3 [67]. The combined GRID [68]/CPCA (consensus principal component analysis) and docking approach
identified regions important for selectivity and yielded insights into important protein-ligand interactions [66]. Four
pockets were identified, termed the S, M, C1 and C2 pockets
(see Fig. 16). In rat nNOS the S pocket is found above the
heme ring and is comprised of residues Phe584, Val567 and
Pro565. The M pocket is located between the substrate catalytic site and the substrate access channel. This pocket includes the residues Asp597, Ser477, Ser568, Gln478,
Arg481, Asn569 and Arg603. The C1 and C2 pockets are a
little removed from the substrate binding cavity and constitute the substrate access channel. The C1 pocket contains
Met336, L337, Glu307, Asn601 and Ser602 while the C2
pocket contains Pro708, Asp709, Pro710 and Gln500.
The S pocket (with the exception of the Asn370Ser difference in iNOS) is identical in the three NOS isoforms used
in this study, (rat nNOS, bovine eNOS and human iNOS).
As such, it is difficult to explain the selectivity exhibited by
some L-arginine analogues when only considering binding in
the S pocket.
From the analysis of several probes, e.g. DRY (hydrophobic probe) and N1+ (charged probe), a ligand with a hydrophobic functional group interacting at the M pocket was
proposed to improve selectivity towards human iNOS. The
M pocket is defined by residues Ser477 and Ser568 in rat
nNOS or Ala262 and Ala353 in human iNOS, which are
postulated as being responsible for selectivity between the
two isoforms. Alternatively, introduction of a positively
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charged functional group would be unfavourable for eNOS
binding in the M pocket. The nNOS M pocket is a more
negative environment than the eNOS M pocket, with rat
nNOS residue Asp597 being replaced by Asn368 in the bovine eNOS M pocket. This highlighted the significance of
the M pocket in the design of isoform selective ligands.
The C1 pocket differs among the NOS isoforms (rat
nNOS, bovine eNOS and human iNOS) at five residues.
Two selective regions were found, the first at residues
Met336 and Leu337 of rat nNOS and another at residues
Glu307, Asn601 and Ser602 of rat nNOS. A histidine residue, His342 in human nNOS, (equivalent to Met336 in rat
nNOS) could potentially be used to guide selective ligand
design.
There are four residues in the C2 pocket that differ across
the NOS isoforms (rat nNOS, bovine eNOS and human
iNOS). The most important residues determined for selectivity are at the rat nNOS Asp709/human iNOS Glu494 positions. The authors postulated that inhibitors with a positively
charged functional group positioned near the Asp709 of rat
nNOS should be selective towards nNOS [66].
2.4.2. 2-Aminopyridine containing inhibitors
The 2-aminopyridine class of NOS inhibitors target the
arginine binding pocket and as their name suggests contain
both a pyridine and amine functionality. It had been previously observed, prior to the elucidation of the rat nNOS crystal structure, that 2-aminopyridines (compound 11) [69] and
quinazolines (compound 12) [70] were inhibitors of NOS
(Fig. 17).
The recent in silico driven era of NOS inhibitor development attempted to build on these known inhibitor scaffolds with Garcin et al. employing an anchored plasticity
approach [71]. The known binding mode of the 2aminopyridine and the quinazoline was conserved in the ar-

Fig. (16). Binding pockets of the rat nNOS arginine active site as defined by Ji et al. [66] with L-NNA bound (compound 7), (PDB:1K2R).
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ginine binding site, and various substituents were attached to
the inhibitor scaffolds in an attempt to improve inhibitor
efficacy and selectivity. It was envisaged that the known
scaffold would maintain inhibitor binding, while the various
substituents would allow the inhibitor to interact with other
parts of the arginine binding site. Of particular interest were
those areas of the binding site that contained residues which
were not conserved across the three isoforms and which
could be exploited so as to improve inhibitor selectivity. Using this method, Garcin et al. developed a novel series of
NOS inhibitors [71] with one of the most efficacious compounds being the human iNOS inhibitor shown in Fig. (18)
(Compound 13).
F

H
N

both ligand binding and NOS enzyme selectivity can be considered for deriving this minimal pharmacophore element.
Building on a previous study [66] the active site of NOS was
again divided into the four pockets S, M, C1 and C2. The S
pocket is found above the heme ring while the M pocket is
located between the substrate catalytic site and the substrate
access channel. Again, the C1 and C2 pockets are slightly
removed from the substrate binding cavity and constitute the
substrate access channel (Fig. 16).

O
N

H2 N

N

Compound 11

F

NH2

Compound 12

Fig. (17). 2-Aminopyridine (compound 11) and quinazoline (compound 12) NOS inhibitors [69,70].

Fig. (18). iNOS selective inhibitor, compound 13, derived from
anchored plasticity studies. This compound has an iNOS IC50 of
0.074 µM with a 100 fold eNOS selectivity and 6 fold nNOS selectivity [71].

Protein crystallization studies of compound 13 (and other
similar compounds) with human iNOS revealed that binding
did indeed occur at the arginine binding site. Similar to the
guanidinium group of arginine, the cis amidine moiety generated a HB to the glutamic acid located at the bottom of the
binding site. The inhibitor also π stacked with the heme
group. The 4-cyanobenzoylpiperidinyl tail of the inhibitor
was located above the heme moiety where it packed with
Gln257, Arg260, Pro344, Ala345 and Arg382. The rigid tail
of the inhibitor forced a rotation of the Gln257 residue of
iNOS. This is referred to by the authors as the Gln open conformation of iNOS. The rotation of Gln257 generates a conformational change at Arg260. This shift is stabilized by a
HB interaction between Arg260 and Thr277. The opening of
this pocket upon inhibitor binding is not observed for eNOS
and nNOS as Thr277 of iNOS is replaced by the sterically
bulkier Asn269/498. The authors suggested that this pocket
opening forms the basis for the iNOS selectivity observed
with these compounds. An image of the Gln open conformation of murine iNOS with compound 13 bound is provided in
Fig. (19).
An alternative approach was adopted by Ji et al., [72]
who described fragment hopping as a de novo inhibitor design approach that focused on the derivation of the “minimal
pharmacophore element” for each NOS isoform. Sites for

Fig. (19). Gln open conformation of iNOS with compound 13
bound. (PDB:3EAI) [68].

For selective nNOS inhibitor design an aminidino group
was positioned close to Glu592; a nitrogen atom was near to
the selective region defined by Asp597 of rat nNOS; three
nitrogen atoms were placed close to the heme propionate to
form a charge-charge interaction and HBs; in the S pocket,
hydrophobic and/or steric interactions played important roles
in ligand binding [72].
Based on each minimal pharmacophoric element, fragments with different chemotypes were generated using a
fragment and a bioisostere library. Fragments were docked
into the active site of nNOS, where the corresponding pharmacophore features were located, and subsequently linked.
To circumvent issues arising from synthetic feasibility,
common chemical bonds in drugs or drug candidates were
considered preferentially [72]. A 2-amino pyridine compound, compound 14, which exhibited nano-molar rat nNOS
inhibitory potency and 1,000-fold rat nNOS selectivity over
bovine eNOS, was identified (Fig. 20).
NH2

H2N

N

-

+

N
H

NH2

Fig. (20). Compound 14 developed by fragment screening [72].
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The 2-aminopyridine 14, (Fig. 20), is quite polar and may
not cross the blood brain barrier (BBB). As a result, Ji et al.
built on this work by designing nNOS inhibitors with increased lipophilicity and optimized in vivo potency and selectivity [73]. In the GRID [68] analysis of rat nNOS, two
hydrophobic areas were identified, one surrounded by
Met336, Leu337, Tyr706 and Trp306 in the C1 pocket and
another lined by Pro565, Ala566, Val567 and Phe584 in the
S pocket (Fig. 16). In addition, two significant areas for
steric probes were identified, one in the S and one in the M
pocket. These regions were used to generate minimal pharmacophoric elements. Several compounds were generated
with the LUDI program [74] which employed lipophilic
fragments for lead optimization. This fragment-based
method allowed the development of compounds with improved pharmaceutical properties and enhanced potency and
selectivity. One such compound is the 2-aminopyridine 15,
which has a Ki of 0.014 µM molar for rat nNOS inhibition
and 2,000 fold selectivity over bovine eNOS and 290 fold
over murine iNOS. The 2-aminopyridine 15 was initially
tested as mixture of diastereomers [73] (Fig. 21). The four
stereoisomers were subsequently resolved [75] (Fig. 21).

The R,R stereoisomer possesses remarkable selectivity,
with the rat nNOS Ki value being 3,800 and 700 times lower
than that for bovine eNOS and murine iNOS respectively. In
rat nNOS, the 4 methyl group is accommodated by a hydrophobic pocket comprised of Met336, Leu337 and Trp306.
This pocket is not available in iNOS, hence the selectivity
over this isoform. The eNOS selectivity is more difficult to
explain as the crystal structure studies suggest that the binding mode for 15 R,R in eNOS and nNOS is the same [75].
Some selectivity differences between the two isoforms can
be explained by residue differences between the eNOS and
nNOS arginine binding pockets, with Asp597 in nNOS becoming Asn in eNOS and Met336 in nNOS becoming Val in
eNOS. However mutation studies indicated that these residue
differences were not the only contributory factors for selectivity [75]. Mutation studies also indicated that the flexible
Tyr706 contributes significantly to binding in nNOS, while
contributing very little to binding in eNOS. Therefore, targeting the Tyr706 site with these new flipped binding mode
compounds offers the potential of highly selective and efficacious nNOS inhibitors.
Compounds such as 15 S,S and 15 R,R have great potential as nNOS inhibitors. However, their development was
hampered by their somewhat poor “drug-like” properties as
both 15 S,S and 15 R,R have a large number of rotatable
bonds and contain several ionisable groups. Attempts have
been made to improve the drug-like features of these compounds and to make them more pharmacokinetically and
pharmacodynamically favourable [76]. These studies resulted in further modifications to the 2-aminopyridines and
generated compounds such as 16 and 17, shown in Fig. (22).

The binding modes of the enantiomers 15 S,S and 15 R,R
with rat nNOS were reported in detail [75]. Compound 15
S,S interacts via HBs between the conserved Glu592 at the
bottom of the arginine pocket and the 2-aminopyridine on
the inhibitor. Water mediated HBs formed with Asp597 and
the 2-aminopyridine formed a π-π interaction with the heme.
The flourophenyl arm was located in the hydrophobic pocket
formed by Met336 and Leu337 (Fig. 15). This is referred to
as the “normal” binding mode of nNOS inhibitors by the
authors, with the 2-aminopyiridine interacting with Glu592.
Interestingly the R configured inhibitor (15 R,R), adopted a
different and novel binding mode with rat nNOS. This
“flipped” binding mode saw the flourophenyl group orientated above the heme moiety. This then formed a π stacking
interaction with the porphyrin ring. The 2-aminopyridine
motif extended away from the heme moiety and induced a
conformational shift in Tyr706, causing this residue to move
away from the aminopyridine. The aminopyridine then
formed a bifurcated salt bridge with the heme propionate A,
as well as a π stacking interaction with the Tyr706. HB interactions are also observed between the pyrrolidine ring and
the heme propionate B.

Compound 16 has a Ki of 7 nM for rat nNOS, 2,667 fold
selectivity over bovine eNOS and 806 fold selectivity over
murine iNOS [76]. Compound 16 was shown to adopt the
flipped mode of binding (Fig. 23), as previously described,
where the 2-aminopyridine interacts with Tyr706 to improve
the binding affinity for nNOS [77]. As before, inverting both
stereocenters (compound 17) resulted in a switching of binding mode to the “normal” mode (Fig. 24), indicating the crucial role stereochemical considerations must play in nNOS
inhibitor design (Figs. 23 and 24). Compound 17 has a Ki of
220 nM for rat nNOS, 270 fold selectivity over bovine eNOS
and 60 fold selectivity over murine iNOS [78].
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Fig. (21). Unresolved aminopyridine 15 [73] and the subsequently resolved stereoisomers [75]. The 3S,4S (compound 15 S,S) and 3R,4R
(compound 15 R,R) stereoisomers had Ki values of 52.2 nM and 5.3 nM respectively for rat nNOS.
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Other modifications have been made to these scaffolds,
such as introducing a cyclopropyl ring or a methyl group
adjacent to the fluoro substituted aromatic ring (compounds
18 and 19) [79]. Difluoroination at this position has also
been examined, compound 20. This has IC50 values of 0.170
µM, 0.046 µM and 0.080 µM for rat nNOS respectively
[77,79]. All compounds were tested as racemates (Fig. 25).

Finally, region C could be an aminopyridine fragment to
enhance affinity through the bifurcated HBs with heme
propionate D and the π-stacking interaction with Tyr706.
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Compound 17
Fig. (22). Modified 2-aminopyridine, compound 16 and its diastereomer, compound 17 [76].
Fig. (24). Compound 17, in the normal binding mode.
(PDB:3NLK). Note how the Y706 does not position itself to interact with the flourophenyl ring [77].

Fig. (23). Compound 16, in the flipped binding mode (PDB:3NLM)
[77]. Note how Y706 is orientated to interact with the 2 aminopyridine ring.

Huang et al. [76] also developed a series of pyrrolidinebased 2-aminopyridines that exhibited a “normal” and
“flipped” binding mode in rat nNOS. Both the binding mode,
and the mechanism by which the ligand leaves the binding
pocket of nNOS, was explored using steered molecular dynamics (SMD). In the SMD approach, forces are applied to a
ligand to manipulate its structure by pulling it along desired
degrees of freedom. Regions A, B and C were defined in the
binding site (Fig. 26) and the type of moiety that could bind
in each region was postulated. Region A could bind an aromatic ring facilitating stacking with the heme and interactions with Glu592. Region B could be the anchoring component that would interact with heme propionate A or Asp597.

Fig (25). Cyclopropyl (compound 18) [79], methyl (compound 19)
[79] and difluoro (compound 20) [77] substituted scaffolds.

A series of compounds containing two pyridine rings
were synthesised to validate the simulation predictions [76].
Compound 21 (Fig. 27) exhibited a Ki of 0.03 µM for rat
nNOS with a rat nNOS over bovine eNOS selectivity of
1,117 and a rat nNOS over murine iNOS selectivity of 619.
Compound 21 also demonstrated improved membrane permeability, at 3 µM, for the aminopyridine based nNOS inhibitors. The metabolic stability of 21 was also examined.
The in vitro metabolic rate was 0.02 (nmol/min/mg protein)
with 85% of compound 21 remaining after 60 min in the
presence of NADPH [76].
Despite the success of 21 and other similar compounds,
the chiral pyrrolidine containing aminopyridine scaffold is
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not particularly suitable for further development due to synthesis and purification difficulties. In addition, the scaffold
was not very drug like, having multiple ionisable groups and
poor BBB characteristics. As previously discussed, reports
on the 2-aminopyridine motif indicated that it was capable of
binding to NOS in two orientations, the “normal” and
“flipped” depending on the stereochemistry of the pyrrolidine ring substituents. Xue et al. reasoned that by combining two identical 2-aminopyridine motifs via a central
linker both binding modes could be achieved with a single
compound [80]. The most potent compound to result from
this structure activity relationship (SAR) study was compound 22 (Fig. 28) which had a Ki of 25 nM for rat nNOS,
and a 107 and 58 fold selectivity over bovine eNOS and
murine iNOS respectively [80].

Fig. (26). Huang's regions A, B and C of the rat nNOS arginine
binding pocket [76] (PDB: 1K2R, unpublished).
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expected, that compound 22 used one of the 2-aminopyridine
moieties to form a network of HBs with Glu592 and Trp587.
The second 2-aminopyridine moiety formed HB interactions
with one of the heme propionates as well as a π-π interaction
with Tyr706. Unexpectedly, a second molecule of compound
22 binds to the BH4 binding site by using the central pyridine
nitrogen to interact with the zinc atom present in the BH 4
site. This results in the displacement of the BH4 and a rearrangement of several residues, in particular Arg596, which
moves to interact with Glu592 and Asp600 of the substrate
binding site. This movement opens a second zinc binding
site in nNOS. The binding of a second zinc atom results in a
tightening of the dimer interface in nNOS. This opening of a
second zinc binding site is not observed in eNOS, potentially
due to the tighter dimer interface of this enzyme. This may
explain the selectivity of compound 22 for nNOS over
eNOS.

Fig. (29). Dual diaminopyridine compound 22 binding to both the
arginine and the BH4 binding sites. (PDB: 3N5W) [81].

Several pharmaceutical companies have also explored the
use of 2-aminopyridines as nNOS inhibitors. In a 2004
study, Pfizer published a series of eight compounds which
inhibited human nNOS, the most efficacious of which was
compound 23, with a IC50 of 54 nM [82] (Fig. 30). Studies
exploring the binding mode of this family of compounds
were not published. Animal studies employing the Pfizer
compounds were mentioned in their 2004 paper but did not
appear in the literature to the best of our knowledge.

Fig. (27). Huang et al.’s aminopyridine, compound 21 [76].
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Fig. (28). Xue et al.’s compound 22 [80].

One of the most interesting features of compound 22 was
its binding mode as determined by crystallization of compound 22 with rat nNOS (Fig 29). [81] It was observed, as

Fig. (30). Pfizer’s 2-aminopyridine, compound 23 [82].

2.4.2.1. MD Studies of Binding Modes of L-NNA and 2Aminopyridines
Compound 13, Fig. (18) and compound 15 R,R, Fig.
(21) were previously synthesised and evaluated by Garcin
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et al. [71] and Ji et al. [75] respectively. Recently, Oliveira
et al. studied the precise binding mode of L-NNA and the
protonated forms of 13 and 15 R,R (Fig. (31) using computational methods. Oliveira et al. first validated their compound docking protocol by re-docking the crystal structure
ligand into the binding pocket. Following docking of the
protonated versions of compound 13 and 15 R,R they implemented 8 ns MD simulations for murine iNOS, bovine
eNOS and rat nNOS monomers [83]. MD simulations are
frequently used to monitor interactions and conformational
changes over a time period in an effort to incorporate receptor/ligand flexibility and induced fit into studies. This
publication offered an excellent insight into the predicted
binding modes of the two main nNOS inhibitor classes,
substituted arginines and 2-aminopyrines, and so will be
discussed in detail.

Fig. (31). Protonated versions of compound 13 [71] and compound
15 R,R [75] computationally studied by Oliveira et al. [83]. The
medicinal chemistry papers of Garcin et al. [71] and Ji et al. [75]
reported the original synthesis and evaluation of 13 and 15 R,R
from which the protonated species shown here are derived.

L-NNA is moderately selective for nNOS over eNOS and
iNOS with IC50 values of 0.29 µM, 0.35 µM and 3.1 µM
respectively. The MD simulations revealed that this selectivity was due to two binding modes which L-NNA could
adopt. In nNOS, the inhibitors bind in an “extended” conformation (Fig. 13). This is facilitated by an interaction
which forms between the L-NNA carbonyl group and
Arg481. This interaction cannot be achieved in iNOS due to
a change of Asn498 in nNOS to Thr277 in iNOS. In nNOS,
Asn498 induces a rotation in Arg481, allowing Arg481 to
interact with the carbonyl group of L-NNA. In iNOS, Thr277
does not induce rotation in the corresponding arginine
(Arg260). L-NNA therefore adopts a “curled” conformation
in iNOS, pushing the carbonyl group close to Asp376. This
results in electronic repulsion between the inhibitor and the
binding site. This explains the higher binding affinity of LNNA for nNOS over iNOS.
L-NNA uses this “curled” mode of binding in eNOS for
similar reasons. The inhibitor is slightly more potent against
eNOS than iNOS due to the change of Asp376 in iNOS to
Asn368 in eNOS. This mutation reduces the electronic repulsion between the binding site and L-NNA in eNOS, which
results in tighter binding. The affinity of the protonated
aminopyridine 13 for iNOS could be explained by the formation of an iNOS specific sub-pocket upon binding. The ability of Glu363 to adopt different conformations has already
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been observed in X-ray crystal structures. The lack of affinity for eNOS was associated with a conformational change in
Glu363 [84,85].
In all three isoforms the protonated version of 13 adopts
the “normal” binding mode, with the 2-aminopyridine moiety positioned near the heam moiety, allowing it to form a
bidentate HB with a Glu residue (Glu592 in rat nNOS,
Glu363 in bovine eNOS and Glu371 murine iNOS). The
binding of the 2-aminopyridine moves the pyridine ring parallel with the heme in iNOS and nNOS, thus facilitating
formation of π- π interactions between the two aromatic
rings. The bulkier residues of the eNOS binding pocket do
not allow the aminopyridine and the heme rings to orientate
themselves parallel to each other. Therefore the π- π interaction does not form in eNOS. Oliveria et al. suggest that this
explains the lower affinity of protonated compound 13 for
eNOS over iNOS and nNOS. In iNOS and nNOS the π- π
interaction pushes the cyanobenzyl above the heme moiety
allowing it to interact with Gln257 in iNOS and Gln478 of
nNOS. In iNOS, this induces the Gln “open” conformation
as previously described by Garcin [71]. The Gln “open” conformation is not observed for nNOS, thus explaining why the
protonated version of compound 13 favours iNOS over
nNOS.
The MD simulations suggested why the protonated form
of compound 15 R,R favours nNOS binding over eNOS or
iNOS. Binding of the protonated compound 15 R,R to eNOS
results in rotation of Glu363 with an associated energy penalty of 1-2 kcal mol -1 [83]. Also, the nNOS arginine binding
pocket was calculated to have a volume of 2203 +/- 8.3 Å3,
while eNOS is slightly larger at 2489.0 +/- 7.7 Å3 [83]. The
larger pocket of eNOS is suggested to result in weaker Van
der Waals interactions between the protonated form of 15
and eNOS. In iNOS, it was observed that the fluorophenyl
group is not parallel to the heme moiety while in nNOS and
eNOS the two rings are parallel, thus enabling π- π interactions. This may explain why the protonated compound 15
R,R is not as potent against iNOS as it is for eNOS and
nNOS.
2.4.3. Thiophene Scaffold Inhibitors
AstraZeneca have published several thiophene containing compounds that act as NOS inhibitors. These compounds retained the same “normal” binding interactions
within the rat nNOS arginine pocket where the amidine
interacts with the conserved Glu592 and the secondary
amine forms an interaction with the heme propionate [86].
The chlorophenyl ring is accommodated by the hydrophobic pocket consisting of Tyr706, Leu337 and Met336 and
the interaction is further stabilised by pi stacking with the
Tyr706 aromatic ring. Compound 24 has IC50 values of
0.035 µM, 3.5 µM and 5 µM against nNOS, eNOS and
iNOS respectively (Fig. 32).
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Fig. (32). AstraZeneca’s thiophene based inhibitor, compound 24
[86].
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Sanofi-Aventis have also examined thiophene scaffolds
as potentially selective nNOS inhibitors. In a 2011 publication Liang et al. reported a series of compounds with IC50
values ranging from 17 nM to 706 nM against nNOS [87].
The most potent of these was compound 25 (Fig. 33). This
displayed a 1,664 fold selectivity for rat nNOS over bovine
eNOS.

Fig. (33). Compound 25, with IC50 of 17nM for rat nNOS [87].

Neuraxon employed a thiophene/guanidinium combination in their SAR studies [88]. Here they developed a series
of compounds containing a thiophene, a guanidinium group
and a hydrocarbon chain linked to an amine functionality.
Their most successful inhibitor was compound 26 (Fig. 34)
with an IC50 of 97 nM for human nNOS [88]. This compound displayed 33 fold and greater than 100 fold, selectivity over human eNOS and human iNOS respectively.
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Fig. (34). Neuraxon’s nNOS inhibitor compound 26 and the secondary amine version developed to ameliorate hERG channel interactions, compound 27 [88].

Replacement of the methyl group on the tertiary nitrogen
with a hydrogen (compound 27, Fig. 34) was observed to
greatly reduce hERG channel interaction, with the IC50 increasing to 139 nM. This secondary amine containing compound was observed to be orally bioavailable and effective in
the Chung pain model of rats [89]. The binding mode of this
compound has not been elucidated to the best of our knowledge.
2.4.4. FeS Coordinating Inhibitors
Imidazole containing compounds have also been observed to bind to the arginine binding site, but in a slightly
different manner. This class of compound coordinate to the
heme Fe at the centre of the active site via an imidazole nitrogen. Imidazole itself is a weak inhibitor of nNOS, with an
IC50 of 290.6 µM [90]. Various substituents have been added
to imidazole in an attempt to improve its efficacy as a nNOS
inhibitor. These substituents include phenyl rings (compound
28) [91] and various amino acids (compound 29) [92, 93]
(Fig. 35).

NH2
Compound 29

Other heme co-ordinating inhibitors have been designed
using in silico methods. L-thiocitrulline, an arginine analogue
with the terminal guanidine-nitrogen replaced by sulphur,
was active against rat nNOS and reported to coordinate to
the heme iron [94]. Litzinger et al. [95] proposed combining
the key features of L-thiocitrulline with amino acid substituted imidazoles. This new class of inhibitor was docked
with rat nNOS using the FlexX [96] program and compound
30 (Fig. 36) was predicted to be positioned with the sulphur
close to the heme and coordinated to the Fe.
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Fig. (35). Phenyl [91] and amino acid [93] substituted imidazoles,
compounds 28 and 29, with nNOS IC50 values of 25 µM and 19 µM
respectively.
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Fig. (36). Iron co-ordination nNOS inhibitors, compounds 30 and
31 [95,97].

Compound 30 exhibited good potency (Ki of 0.37 uM)
and moderate selectivity for rat nNOS (185 fold for rat
nNOS over bovine eNOS and 3.12 fold for rat nNOS over
murine iNOS). In contrast to the docking predictions, experimental difference absorption spectra indicated a type I
spectrum when compound 30 was added to imidazole saturated nNOS. Absorption spectra categorised as a type I spectra, with a peak at ~400 nm and a trough at 437 nm, are indicative of a pentacoordinate high spin heme iron. While a
type II spectrum, such as that for a known Fe coordinating
ligand (e.g. imidazole), displays a peak at 432 nm and a
trough at 393 nm. The observed type I spectrum indicates
that the sulphur containing chain does not interact with the
heme iron as predicted. Subsequently, the group postulated
that the sulphur containing chain binds preferentially in the
hydrophobic pocket at the top of the active site [95].
The same group then analyzed potential ligand-enzyme
interactions in the hydrophobic pocket defined by Pro565,
Val567, and Phe584 of rat nNOS [97]. This pocket can also
accommodate small alkyl groups, with inhibitors anchored in
the active site through a HB with Glu592. Based on this
analysis compound 31 (Fig. 36) was designed, which was
confirmed to be a type II ligand by UV-vis spectrophotometry and crystallography (type II inhibitors convert the highspin heme of BH4-nNOS to a low spin state, resulting in a
red shift in the Soret absorption and a type II visible difference spectrum) [97]. The crystal structure of compound 31
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with rat nNOS revealed that the two methylene groups, separating the amidine from the sulphur, afforded the flexibility
needed to place the sulphur directly over the heme iron. The
terminal ethyl group fits into the hydrophobic pocket formed
by Pro565, Val567 and Phe584 and the Fe-S distance is 2.52.6 Å (Fig. 37).
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HBs through its 6-NH2 group with Ala446, Trp447 and
Val449 of nNOS.
Table 2.

Xu et al.’s predicted nNOS inhibitors [99].

Structure

Fig. (37). Compound 31 co-crystallized with rat nNOS (PDB:3JT4)
[97].

2.4.5. Recent Advances in nNOS Inhibitor Design & Optimization
Virtual screening is often used as an alternative to high
throughput screening, in an effort to reduce both cost and
time [98]. The approach can be validated initially through
the use of theoretical test/validation sets and subsequently
through experimental evaluation of the identified compounds. Xu et al. [99] performed a tiered virtual screening
study incorporating development of a seven feature NOS
pharmacophore, a Comparative Molecular Field Analysis
(CoMFA) comparison and docking studies using a rat nNOS
crystal structure. The pharmacophore model incorporated
three hydrophobes, one donor atom, one acceptor atom and
two positive nitrogens and was in general agreement with the
CoMFA model. Here, tiered virtual screening of the Specs
database of 197,000 compounds was pursued by filtering
first by the pharmacophore query, by Lipiniski rules and by
Qfit [100]. Subsequently, the filtered compounds were further examined by flexible docking. From this 10 compounds
were identified as potential selective human nNOS inhibitors
but remain to be experimentally validated. The top three
ranking compounds from this screen are shown in Table 2.
Recently, Kumar et al. [101] developed a QSAR model
of a series of 3,4-dihydro-1-isoquinolinamines and thienopyridines that were reported as potent, highly selective inhibitors of nNOS and eNOS. The QSAR models for nNOS
and eNOS inhibition potency were indicated to involve a
hydrophobic (ClogP) and a steric (calculated molar refractivity, CMR) interaction respectively. Through docking studies
the possible orientations of the compounds with the enzymes
were modelled. Compound 32 (Fig. 38) was predicted to
form a HB through the 6-NH2 group with Pro450 and 3 HBs
between the 10-NH2 group and Val449, Pro450 and Pro451
of eNOS. Alternatively, compound 33 was predicted to form

NH2
S

N
NH2
Compound 32

Dock
Score

QFIT

8.29

65.74

8.20

65.74

8.01

65.82

S
S
Compound 33

N
NH2

Fig. (38). Kumar et al.’s compounds 32 and 33 utilised in a QSAR
study [101].

3. PHARMACOKINETICS OF nNOS INHIBITORS
The BBB blocks certain drugs, chemical compounds and
viruses from gaining access to the CNS from the bloodstream. In general, CNS drugs have a smaller range of molecular weights, and smaller number of hydrogen bond donor
and acceptors than general therapeutics [102]. A large number of charges and hydrogen bond donors can impede the
ability of molecules to cross the BBB and thereby limit the
effectiveness of potential neurological therapeutics.
In the nNOS arena, a number of medicinal chemistry approaches have been pursued to improve PK properties
[103,104]. For example, a prodrug approach was employed
that involved replacing one of the secondary amino groups
on a pteridine NOS inhibitor (which binds in the BH 4
pocket) with an amide or carbamate [36], (scaffolds shown
in Fig. 6). This was reported to improve BBB penetration by
lowering the charge, removing two HBDs and raising the
predicted logD [36]. Additionally, amino groups which exhibited a high pKa have been replaced by ethers and amides
in 2-aminopyridines [105], (Fig. 39). The resultant ether analogue maintained a similar potency and selectivity but with
an increased ability to penetrate the BBB, as evidenced by an
increased brain to blood concentration ratio [105]. Acetylated and carbamoylated prodrug analogues of compound 21,
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reported by Silverman and co-workers, have increased lipophilicity and lowered charge, but surprisingly, did not cause
an increase in BBB penetration (Fig. 40) [106]. Over a 20
minute experiment there was little difference between the
overall brain concentrations of the tested prodrug analogues
of 21.
H
N
H2N

N

4 3 N
H

H
N

F

17

formation, which would decrease the overall polarity of the
compound and potentially improve BBB permeability. Once
the inhibitor bound to nNOS it might form alternative intermolecular interactions and stabilize an “open” conformation
[112] (Fig 42). Some synthesised compounds capable of
intramolecular HB formation exhibited an improved relative
permeability index (RPI), indicative of an increased cell
membrane penetration ability e.g. a RPI of 3.1 was observed
for compound 34 (Fig. 41). However, it appears that incorporation of an intra-molecular HB was not sufficient to enhance
cell membrane permeability for other compounds with lipophilicity playing a larger role [112].

Compound 15 S,S
O

H
N
H2N

N

O

H
N

H
N

HN

F

Compound 16
Fig. (39). Compound 15 S,S [72] with a secondary amine, and compound 16 [73] with an ester linkage which were used to study how
substitution patterns affected passage of nNOS inhibitors across the
BBB [105].

O
H2N

N

Fig. (41). Labby et al.’s aminopyridine based inhibitor, compound
34. This can form intramolecular HB between the secondary amine
hydrogen and the methyl ester oxygen. This interaction is lost on
inhibitor binding to nNOS [112].

Fig. (40). Compound 21 and three prodrug analogues of same. Silverman et al. 2009 [106].

Fig. (42). Compound 34 bound to rat nNOS arginine site. The intramolecular hydrogen bond interaction between the secondary
amine hydrogen and the oxygen of the methyl ester is disrupted on
inhibitor binding. This was referred to as “open” binding of the
inhibitor (PDB: 3TYM) [112].

The addition of an intramolecular HB is another known
strategy used in PK and BBB optimisation of novel inhibitors for a variety of enzymes [107-111]. In an effort to exploit this strategy, nNOS aminopyridine inhibitors were designed with intramolecular hydrogen bonding motifs in the
hope of improving cell membrane permeability [112]. In this
study, inhibitors such as compound 34 were hypothesised to
form a “closed” conformation through intramolecular HB

Xue et al. [77] introduced an electron withdrawing CF2
moiety to aminopyridine inhibitors in an effort to reduce the
basicity of their hit compound and improve its bioavailability
(Fig. 43). Molecular Mechanics Poisson-Boltzmann/Surface
Area (MM-PBSA) calculations, used to compute the free
energy for various protonation states of the molecules, were
performed and compared with the experimental free energy
data. This confirmed the likelihood that the low pKa amino
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group is partially protonated when bound to the nNOS active
site. The experimental pharmacokinetic data illustrated that
the addition of CF2 had a marked effect on in vivo stability
and oral bioavailability. For example, compound 20 exhibited an in vivo compound half-life (t½) for i.v. dosing at 1
mg/kg in rats of 7.5 hr; a t½ for oral dosing of 3.7 hr and an
oral bioavailability of 22.2 % whereas compound 16 had a t½
for i.v. dosing at 1 mg/kg in rats of 0.33 hr; a t½ for oral dosing that was too low to measure and an oral bioavailability of
essentially 0 %, (Fig. 43).
H
N
H2N

N

O

H
N

F

Compound 16
H
N
H2N

N

O

H
N

F F

F

Compound 20
Fig. (43). Aminopyridine inhibitors 16 and 20, as presented by Xue
et al. [77].

In recent years, Kumar et al. [113] examined a number of
computational BBB filter models and concluded that there
remains an urgent need to generate larger and more diverse
datasets with accurate measurements of logBB values (the
logarithm value of brain to plasma concentration ratio). Additionally, other factors can influence BBB penetration e.g.
plasma protein binding, active efflux from the CNS etc.
However, Ji et al. [72] advocated early ADME/Tox considerations in de novo nNOS compound design, as this would
allow the functional groups that potentially effect metabolic
stability and toxicophores to be taken into account during the
generation of the focused fragment library and the linking of
fragments. Such ADME/Tox considerations included oral
bioavailability (rule of 5); blood brain distribution; and
metabolic
stability
(Metasite,
http://www.moldiscovery.com/software/metasite). The group
of Ji et al. used a property based strategy to evaluate
ADME/Tox effect of molecules [114]. A similar approach
has been applied to other NOS enzymes. Recently, Kartasasmita et al., [115] examined Asiatic acid derivatives as
iNOS inhibitors. Their docking study was coupled with a
rudimentary ADME prediction using PreADMET
(http://preadmet.bmdrc.org). Where experimental PK data
was available, the prediction tool was in good agreement for
human intestinal absorption (HIA). Such computational tools
can be used to focus at an early stage, on those inhibitors
which have appropriate properties for oral administration.

signed and utilized as nNOS inhibitors targeting a selection
of sites, including the BH4, CaM, NADPH and the arginine
binding sites.
Efforts have been made to inhibit the binding of the crucial co-factor BH4 so as to slow NOS activity. This between
NOS isoforms. The concern remains that in the absence of
BH4 there may be a build-up of potentially harmful free radical species. Work has been conducted on inhibiting NOSCaM interactions. Interfering with CaM itself could have
potentially serious consequences in vivo owing to the wide
range of processes which CaM regulates. Also, targeting
protein-protein interaction sites is considered to be difficult
as the surfaces are usually solvent exposed and do not favour
strong binding interactions. For the NADPH binding site of
NOS, a nucleotide moiety mimicking NADPH linked to a
conjugated push-pull chromophore with non-linear absorption properties has been explored as both a trigger and a
shutter. However, due to the vast array of enzymes which
bind NADPH and the tendency of these sites to be well conserved, it is likely that any imaging agent would suffer from
a lack of specificity.
The best explored classes are the L-arginine mimics,
which unsurprisingly replicate the binding mode of the natural substrate, and the 2-aminopyridines, which have been
observed to bind in either a flipped or non-flipped orientation
depending on substitution patterns. Other classes, including
imidazole and thiophene analogues, have also been examined. While efficacious and selective compounds have been
identified, challenges remain surrounding the suitability of
these compounds for further development due to their pharmacokinetic properties.
Further development in the area of nNOS inhibition will
rely on development of an all human isoform assay system.
Throughout the literature there is inconsistency in what isoform of nNOS is used for testing (rat, porcine, human etc).
There is also inconsistency in the types of assay used to test
inhibitory compounds. These can vary between Griess based
assays, haemoglobin conversion assays, radiolabelled assays
and whole cell assays. This is compounded by the use of
various isoforms for selectivity testing and examination of
binding modes (comparing inhibition of rat nNOS with bovine eNOS for example). This issue should be somewhat
addressed by the very recent publication of the first human
nNOS crystal structure [116]. A move to a uniform method
of testing (both NOS isoform and assay system) will allow
robust comparison of results and development of more efficacious and selective nNOS inhibitors.
As evidenced in this review a substantial body of work
has been conducted on nNOS inhibition using a variety of
approaches. Continued work in this area has the potential to
yield a clinically viable nNOS inhibitor in the near future,
which could significantly improve the quality of life for
those suffering from debilitating illness.

CONCLUSION AND FUTURE PERSPECTIVES

ABBREVIATIONS

A focus of this review was on the recent use of computational techniques in the design and optimization of nNOS
selective inhibitors and an analysis of the success of such
approaches. A variety of compound classes have been de-

BBB

= Blood brain barrier

CMR

= Calculated molar refractivity

CaM

= Calmodulin
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CBR

= Calmodulin binding region

CNS

= Central nervous system

CoMFA = Comparative molecular field analysis
CoMSIA = Comparative molecular similarity index analysis
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[2]
[3]
[4]

CPCA

= Consensus principal component analysis

cGMP

= Cyclic guanosine 3’,5’-monophosphate

eNOS

= Endothelial nitric oxide synthase

[6]

FAD

= Flavin adenine dinucleotide

[7]

FMN

= Flavin mononucleotide

HB

= Hydrogen bond

HBA

= Hydrogen bond acceptor

HBD

= Hydrogen bond donor

iNOS

= Inducible nitric oxide synthase

LBDD

= Ligand based drug design

[11]

MD

= Molecular dynamics

[12]

[5]

[8]
[9]
[10]

NADPH = Nicotinamide adenine dinucleotide phosphate
nNOS

= Neuronal nitric oxide synthase

[13]

L-NNA = Nω-nitro-L-arginine
L-NOHA = N-hydroxy-L-arginine
NO

= Nitric oxide

NOS

= Nitric oxide synthase

NMR

= Nuclear magnetic resonance

PK

= Pharmacokinetics

Por

= Porphyrin

QSAR

= Quantitative structure activity relationship

RNS

= Reactive nitrogen species

ROS

= Reactive oxygen species

RPI

= Relative permeability index

SMD

= Steered molecular dynamics

SBDD

= Structure based drug design

BH4

= Tetrahydrobiopterin

[14]

[15]
[16]

[17]
[18]

[19]
[20]
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